1-[(3-methyl-4-nitrophenyl)carbonyl]-1H-imidazole

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(3-methyl-4-nitrophenyl)carbonyl]-1H-imidazole
• 英文别名: imidazol-1-yl-(3-methyl-4-nitrophenyl)methanone
• 化学式: C₁₁H₉N₃O₃
• 分子量: 231.211
• InChiKey: OVSNZHLPOWDQAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  80.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[(3-methyl-4-nitrophenyl)carbonyl]-1H-imidazole 在 一水合肼 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 5-(3-methyl-4-nitrophenyl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazole
  参考文献：
  名称：

  New Antimitotic Agents with Activity in Multi-Drug-Resistant Cell Lines and in Vivo Efficacy in Murine Tumor Models

  摘要：

  During a screen for compounds that could inhibit cell proliferation, a series of new tubulin-binding compounds was identified with the discovery of oxadiazoline 1 (A-105972). This compound showed good cytotoxic activity against non-multi-drug-resistant and multi-drug-resistant cancer cell lines, but its utility in vivo was limited by a short half-life. Medicinal chemistry efforts led to the discovery of indolyloxazoline 22g (A-259745), which maintained all of the in vitro activity seen with oxadiazoline 1, but also demonstrated a better pharmacokinetic profile, and dose-dependent in vivo activity. Over a 28 day study, indolyloxazoline 22g increased the life span of tumor-implanted mice by up to a factor of 3 upon oral dosing. This compound, and others of its structural class, may prove to be useful in the development of new chemotherapeutic agents to treat human cancers.

  DOI：

  10.1021/jm010231w
• 作为产物：
  描述：

  3-甲基-4-硝基苯甲酸 、 N,N'-羰基二咪唑 反应 0.08h， 生成 1-[(3-methyl-4-nitrophenyl)carbonyl]-1H-imidazole
  参考文献：
  名称：

  一种环境可持续的机械化学合成异羟肟酸衍生物的途径

  摘要：

  提出了通过高能机械化学活化将羧酸简单，经济地转化为异羟肟酸衍生物的方法。该球磨方法论已应用于多种羧酸，大大改善了与此类分子相关的纯化问题，而这些问题仍然是经典方法学的主要瓶颈之一。

  DOI：

  10.1002/adsc.201600350

文献信息

• Tetrahydropteridines useful as inhibitors of protein kinases
  申请人：Charrier Jean-Damien

  公开号：US20090062292A1

  公开（公告）日：2009-03-05

  The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及作为蛋白激酶抑制剂有用的化合物。该发明还提供包括所述化合物的药学上可接受的组合物，以及在治疗各种疾病、症状或紊乱中使用这些组合物的方法。该发明还提供制备本发明化合物的方法。
• Pyrimidinones as Casein Kinase II (CK2) Modulators
  申请人：Rice Kenneth D.

  公开号：US20090215803A1

  公开（公告）日：2009-08-27

  A compound having Formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R 1 and R 2 are defined in the specification; pharmaceutical compositions thereof; and methods of use thereof.

  具有化学式（I）或其药用可接受的盐的化合物，其中X、R1和R2在规范中定义；其药物组成；以及使用方法。
• Biology-oriented drug synthesis (BIODS): In vitro β-glucuronidase inhibitory and in silico studies on 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl aryl carboxylate derivatives
  作者：Uzma Salar、Khalid Mohammed Khan、Muhammad Taha、Nor Hadiani Ismail、Basharat Ali、Qurat-ul-Ain、Shahnaz Perveen、Mehreen Ghufran、Abdul Wadood

  DOI：10.1016/j.ejmech.2016.11.031

  日期：2017.1

  Current study is based on the biology-oriented drug synthesis (BIODS) of 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl aryl carboxylate derivatives 1–26, by treating metronidazole with different aryl and hetero-aryl carboxylic acids in the presence of 1,1′-carbonyl diimidazole (CDI) as a coupling agent. Structures of all synthetic derivatives were confirmed with the help of various spectroscopic techniques such

  当前的研究基于2-（2-甲基-5-硝基-1 H-咪唑-1-基）乙基芳基羧酸酯衍生物1-26的生物导向药物合成（BIODS），方法是用不同的芳基和甲腈处理甲硝唑。 1,1'-羰基二咪唑（CDI）作为偶联剂存在下的杂芳基羧酸。借助于各种光谱技术，例如EI-MS，1 H - NMR和13 C NMR ，确认了所有合成衍生物的结构。还发现CHN元素分析与计算值一致。评价了合成衍生物以检查其对β-葡萄糖醛酸苷酶的抑制活性，这表明除极少数衍生物外，所有衍生物均在IC范围内表现出良好的抑制作用。50  = 1.20±0.01-60.30±1.40  μ相比于标准的M d -saccharic酸-1,4-内酯（IC 50  = 48.38±1.05  μ M）。化合物1，3，4，6，9 - 19，和21 - 24被发现是有效的类似物和显示出优良的活性比标准。有限的结构-活性关系表明，具有吸电子基团（如NO
• Pyrimidinones as Casein Kinase II (CK2) modulators
  申请人：Exelixis, Inc.

  公开号：US08101625B2

  公开（公告）日：2012-01-24

  A compound having Formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1 and R2 are defined in the specification; pharmaceutical compositions thereof; and methods of use thereof.

  一种具有式(I)的化合物或其药学上可接受的盐，其中X，R1和R2在规范中定义；其药物组合物；以及其使用方法。
• PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS
  申请人：Exelixis, Inc.

  公开号：EP1948617B1

  公开（公告）日：2011-07-27